Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other financing activities (2023 - 2024)

Contineum Therapeutics (CTNM) has 2 years of Other financing activities data on record, last reported at $140000.0 in Q1 2024.

  • For Q1 2024, Other financing activities rose 2700.0% year-over-year to $140000.0; the TTM value through Mar 2024 reached $157000.0, changed N/A, while the annual FY2023 figure was $22000.0, N/A changed from the prior year.
  • Other financing activities reached $140000.0 in Q1 2024 per CTNM's latest filing, up from $1000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $140000.0 in Q1 2024 and bottomed at $1000.0 in Q4 2023.